Great Work — Utah

Official Website: Curza

source confidence: Medium status: Useful updated 2026-06-19

Type
source
Status
Useful
Confidence
Medium
Source Type
official-page
URL
https://curza.com
Archive
https://web.archive.org/web/20260608121151/https://www.curza.com/
Archived
2026-06-08
Publisher
Curza
Raw
raw/curza-official-website/2026-08-11-d30bfbbdee18.txt
Retrieved
2026-08-12
Updated
2026-06-19

Summary

Curza's official website describes a small-molecule therapeutics company developing proprietary antibiotic classes focused on infectious diseases, with lead program CZ-02 targeting drug-resistant Gram-negative ESKAPE pathogens via an unexploited bacterial ribosome binding site.

Useful Claims

  • The site positions Curza as a small-molecule therapeutics company with several structurally distinct proprietary drug classes focused on infectious diseases.
  • Lead program CZ-02 is described as a new class of broad-spectrum antibiotics focused on ESKAPE pathogens, especially drug-resistant Gram-negative bacteria.
  • CZ-02 is said to be inspired by a natural product and to target an unexploited binding site on the bacterial ribosome.
  • Additional program areas mentioned include ribosomal antibiotics for ESKAPE "superbugs" and antibiofilm antibiotics for infections such as tuberculosis, diabetic ulcers, Lyme disease, and cystic fibrosis-related infections.
  • The site cites WHO framing of antibiotic resistance as a major global health threat.
  • Company address listed: 650 Komas Drive, Suite 202, Salt Lake City, UT 84108.

Verbatim

"Cūrza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases." — Home page, technology

"Our lead program, CZ-02 is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens, with a focus on drug-resistant Gram-negative bacteria." — Home page, lead program

"Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome." — Home page, lead program

"650 Komas Drive, Suite 202 Salt Lake City, UT 84108" — Home page, contact footer

Reliability Notes

This is an official company source. It is useful for pipeline positioning, mechanism claims, and program structure, but preclinical potency, IND timing, clinical efficacy, and funding totals should be cross-checked with grant announcements, investor press releases, and peer-reviewed data before being treated as high-confidence evidence.

Related Pages

See Also